RANKL/TNFSF11/CD254 Protein, Mouse, Recombinant (hFc)

RANKL/TNFSF11/CD254 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 56 kDa and the accession number is AAC40113.1.

RANKL/TNFSF11/CD254 Protein, Mouse, Recombinant (hFc)

パッケージサイズ	在庫状況	単価(税別)
50 μg	在庫あり	￥ 56,500
100 μg	約5 days	￥ 97,000
200 μg	約5 days	￥ 257,000
500 μg	約5 days	￥ 519,000

バルクのお問い合わせ

生物学的情報	Immobilized mouse Fc-TNFSF11 at 10 μg/ml (100 μl/well) can bind biotinylated human TNFRSF11B-His , The EC50 of biotinylated human TNFRSF11B-His is 0.07-0.17 μg/ml.
説明	RANKL/TNFSF11/CD254 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 56 kDa and the accession number is AAC40113.1.

Species	Mouse
Expression Host	HEK293 Cells
Tag	hFc
Accession Number	AAC40113.1
別名	RANKL, OPGL, Trance, OPG, tumor necrosis factor (ligand) superfamily, member 11, ODF, Ly109l
Construction	The extracellular domain of Mouse TNFSF11 (AAC40113.1) (Arg 72-Asp 316) was fused with the Fc region of Human IgG1 at the N-terminus.
Protein Purity	> 87 % as determined by SDS-PAGE
分子量	56 kDa (predicted)

Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein that belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

参考文献

1. Takayanagi H,et al.(2002) Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res. 4 Suppl 3: S227-32. 2. Nakashima T,et al.(2003) RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 15(3): 280-7. 3. Schwarz EM,et al.(2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther. 9 Suppl 1: S7. 4. Leibbrandt A,et al.(2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143: 123-50.

Calculator

Reconstitution Calculator

Recombinant Proteins Dilute Calculator

Specific Activity Calculator

bottom

RANKL/TNFSF11/CD254 Protein, Mouse, Recombinant (hFc)

参考文献

Calculator

技術サポート

Keywords